FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564398082> ?p ?o ?g. }

• W2564398082 abstract "Melanoma is one the most commonly diagnosed cancers in Australia and while treatment is generally successful if the tumor is identified early, once the disease begins to spread the prognosis is considerably worse. The recent approval of new targeted therapies (Vemurafenib, Dabrafenib and Trametinib) has improved progression-free survival for patients carrying the common V600- B-Raf mutations. However even when these inhibitors are used in combination many tumors still develop resistance and furthermore there is a lack of treatment options available for patients who do not carry the mutated form of B-Raf. Therefore there is a pressing need for new therapeutics to address this deficit. The AP-1 transcription factor family has been shown to play an important role in numerous aspects of melanoma tumorgenesis including cellular proliferation and survival, making these transcription factors attractive targets for new treatments. Therefore, a high throughput screening was performed on several libraries of chemical compounds to identify those capable of inhibiting AP-1 directed transcription in vitro. Two lead compounds (X and BT2) were identified for further testing. From these a number of analogues were produced to modify their activity. Those that showed the most improvement above the leads against several melanoma lines were selected for further testing. The in vitro activity of these compounds was characterised in detail against two human melanoma cell lines, one wild type for B-Raf and one carrying the common V600E mutation. In 2D culture both compounds inhibit melanoma cell proliferation; induce apoptosis and cell cycle arrest and inhibit clonogenic capacity. These compounds have little cytotoxicity (LDH) and retain their activity for at least a month under a variety of environmental conditions. Furthermore in 3D spheroid assays the compounds show similar levels of activity. In vivo proof-of-concept testing is underway to assess the compounds activity in immunocompetent (xenograft) and immunocompromised (allograft) model. In parallel, bioinformatics analysis of mass spectrometry, kinome and microarray data is underway to identify the exact mechanism of action and the specificity of these inhibitors. In summary, the identified compounds show promising anti-melanoma activity in vitro. They inhibit human melanoma growth and clonogenic capacity and induce apoptosis and cell cycle arrest in 2D culture at submicromolar concentrations, comparable to the clinically approved drug Tramatenib. They show little cytotoxicity and also inhibit growth in a 3D spheroid model at submicromolar concentrations. The AP-1 transcription family, in particular c-Jun, have been shown to be important players in the development of melanoma. As such, these compounds may prove to be effective treatments for melanoma irrespective of B-Raf status and warrant further investigation both in vitro and in vivo. Citation Format: Kylie M. Taylor, Ahmad MN Alhendi, Gary Halliday, Lionel Prado-Lourenco. Novel transcriptional inhibitors for the inhibition of melanoma growth. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1647. doi:10.1158/1538-7445.AM2015-1647" @default.
• W2564398082 created "2017-01-06" @default.
• W2564398082 creator A5019636461 @default.
• W2564398082 creator A5023927861 @default.
• W2564398082 creator A5044391659 @default.
• W2564398082 creator A5045165555 @default.
• W2564398082 date "2015-08-01" @default.
• W2564398082 modified "2023-09-27" @default.
• W2564398082 title "Abstract 1647: Novel transcriptional inhibitors for the inhibition of melanoma growth" @default.
• W2564398082 doi "https://doi.org/10.1158/1538-7445.am2015-1647" @default.
• W2564398082 hasPublicationYear "2015" @default.
• W2564398082 type Work @default.
• W2564398082 sameAs 2564398082 @default.
• W2564398082 citedByCount "0" @default.
• W2564398082 crossrefType "proceedings-article" @default.
• W2564398082 hasAuthorship W2564398082A5019636461 @default.
• W2564398082 hasAuthorship W2564398082A5023927861 @default.
• W2564398082 hasAuthorship W2564398082A5044391659 @default.
• W2564398082 hasAuthorship W2564398082A5045165555 @default.
• W2564398082 hasConcept C104317684 @default.
• W2564398082 hasConcept C117262875 @default.
• W2564398082 hasConcept C184235292 @default.
• W2564398082 hasConcept C202751555 @default.
• W2564398082 hasConcept C2776131300 @default.
• W2564398082 hasConcept C2777658100 @default.
• W2564398082 hasConcept C2778472372 @default.
• W2564398082 hasConcept C2778830669 @default.
• W2564398082 hasConcept C2994587330 @default.
• W2564398082 hasConcept C502942594 @default.
• W2564398082 hasConcept C54355233 @default.
• W2564398082 hasConcept C57074206 @default.
• W2564398082 hasConcept C62112901 @default.
• W2564398082 hasConcept C71924100 @default.
• W2564398082 hasConcept C86339819 @default.
• W2564398082 hasConcept C86803240 @default.
• W2564398082 hasConceptScore W2564398082C104317684 @default.
• W2564398082 hasConceptScore W2564398082C117262875 @default.
• W2564398082 hasConceptScore W2564398082C184235292 @default.
• W2564398082 hasConceptScore W2564398082C202751555 @default.
• W2564398082 hasConceptScore W2564398082C2776131300 @default.
• W2564398082 hasConceptScore W2564398082C2777658100 @default.
• W2564398082 hasConceptScore W2564398082C2778472372 @default.
• W2564398082 hasConceptScore W2564398082C2778830669 @default.
• W2564398082 hasConceptScore W2564398082C2994587330 @default.
• W2564398082 hasConceptScore W2564398082C502942594 @default.
• W2564398082 hasConceptScore W2564398082C54355233 @default.
• W2564398082 hasConceptScore W2564398082C57074206 @default.
• W2564398082 hasConceptScore W2564398082C62112901 @default.
• W2564398082 hasConceptScore W2564398082C71924100 @default.
• W2564398082 hasConceptScore W2564398082C86339819 @default.
• W2564398082 hasConceptScore W2564398082C86803240 @default.
• W2564398082 hasLocation W25643980821 @default.
• W2564398082 hasOpenAccess W2564398082 @default.
• W2564398082 hasPrimaryLocation W25643980821 @default.
• W2564398082 hasRelatedWork W1545829378 @default.
• W2564398082 hasRelatedWork W2027203760 @default.
• W2564398082 hasRelatedWork W2041052361 @default.
• W2564398082 hasRelatedWork W2082278315 @default.
• W2564398082 hasRelatedWork W2116733031 @default.
• W2564398082 hasRelatedWork W2126755208 @default.
• W2564398082 hasRelatedWork W2272280391 @default.
• W2564398082 hasRelatedWork W2331369838 @default.
• W2564398082 hasRelatedWork W2332138153 @default.
• W2564398082 hasRelatedWork W2339921159 @default.
• W2564398082 hasRelatedWork W2400206616 @default.
• W2564398082 hasRelatedWork W2742030022 @default.
• W2564398082 hasRelatedWork W2801356018 @default.
• W2564398082 hasRelatedWork W2886256490 @default.
• W2564398082 hasRelatedWork W2887342233 @default.
• W2564398082 hasRelatedWork W2939305283 @default.
• W2564398082 hasRelatedWork W2954753565 @default.
• W2564398082 hasRelatedWork W3154576387 @default.
• W2564398082 hasRelatedWork W3180572238 @default.
• W2564398082 hasRelatedWork W3184501762 @default.
• W2564398082 isParatext "false" @default.
• W2564398082 isRetracted "false" @default.
• W2564398082 magId "2564398082" @default.
• W2564398082 workType "article" @default.